BEAM - Beam Therapeutics - $22.74 Retest - $28 PTBEAM had a nice bullish breakout in today's pre-market session, consolidating in the intraday and show signals of a continuation to retest that $22.74 and push on up into the next range with previous resistance being $28.48.
This comes after announcing FDA Regenerative Medical Status for BEAM-101 to treat Sickle Cell Disease 2 weeks ago.
